TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06666790: DermaSensor Postmarket Surveillance Study

Sponsor: DermaSensor, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 396 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06666790 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06666790 Rescue Dossier →